LL-37 Wound Healing: What Trials Found

The first topical trial

The 2014 placebo-controlled study enrolled 34 people with hard-to-heal venous leg ulcers. It tested topical LL-37 during a four-week blinded treatment phase, after a run-in period, with additional follow-up. This was a small early study of wound treatment rather than a general trial of immune enhancement ^[1].

Two active-treatment groups showed favorable healing signals, but the results were not uniform. For the healing-rate comparison with placebo, one group reached conventional statistical significance and another did not. The highest-concentration group showed no healing difference from placebo ^[1].

The study supported further investigation. It did not establish that increasing exposure would improve healing, and the favorable title should be read alongside the individual comparisons and the small sample.

The larger comparison

The 2021 HEAL LL-37 study evaluated topical LL-37 alongside compression therapy in 148 treated patients with difficult venous leg ulcers. It was a double-blind, placebo-controlled phase IIb trial. Analysis of the full study population found no significant healing improvement compared with placebo ^[2].

A post hoc analysis found favorable results in patients with larger wounds. The investigators described that finding as a reason for a further study designed and powered to assess that subgroup, rather than as confirmation that the overall trial succeeded ^[2].

An exploratory result is not worthless. It changes the next research question: whether patients with a defined wound characteristic benefit. It does not change the answer to the original full-population comparison.

A biomarker study is different

A separate study followed 19 patients with venous leg ulcers and examined their own circulating LL-37. Higher concentrations correlated with healing rates. The investigators did not administer LL-37 as the intervention being tested ^[3].

That distinction matters when several papers are presented together as evidence that a purchased peptide works. A correlation can support a biological hypothesis or suggest a marker worth studying. It cannot establish that adding the substance causes the favorable outcome.

Naturally occurring LL-37 may reflect processes already involved in healing. Only an appropriate intervention comparison can separate the effect of administered treatment from the characteristics of patients whose wounds heal more readily.

Route and background care

The controlled studies discussed here placed the peptide on a specific kind of wound; the larger study also used compression therapy ^{[1, 2]}. Neither tested a systemic injection for immunity, infection prevention or general recovery. Moving from local wound exposure to injection changes the clinical question.

The trial product, route, wound type and accompanying care are part of the evidence. Removing those details leaves a claim much broader than the studies. A seller cannot establish an injectable benefit merely by pointing to a topical trial, whether that trial is positive or negative.

Safety and the practical conclusion

The topical trial reports did not identify major safety concerns under their study conditions ^{[1, 2]}. That is not a demonstration of long-term safety by another route. Short follow-up and modest sample sizes also limit the ability to detect uncommon harms.

The strongest defensible summary is that LL-37 remains an investigational wound-healing approach with mixed findings. The LL-37 monograph provides the separately dated regulatory record. These wound studies should not be used as instructions for self-treatment or as proof of a clinical supply route.

Elsewhere in this index